Company Filing History:
1 out of 38 
1 out of 3 Years Active: 2015
Title: The Innovative Contributions of Maura Pellei in Cancer Treatment
Introduction: Maura Pellei is a notable inventor based in Camerino, Italy, who has made significant strides in the field of oncology. Her work revolves around the development of compounds aimed at treating a variety of human solid tumors, including those that are refractory. With her innovative approach, Pellei has secured a patent for her groundbreaking research that stands to benefit the medical community profoundly.
Latest Patents: Maura Pellei holds a patent for the invention titled "[Cu(thp)4]n[X]-n compounds for the treatment of a broad range of human solid tumors." This involves the synthesization of Copper (I) complexes of the type [Cu(thp)4][X], where thp refers to tris(hydroxymethyl)phosphine, and X designates a counteranion, with n ranging from 1 to 4. This invention is poised to serve as antineoplastic agents against solid tumors in humans, showcasing her dedication to advancing cancer therapy.
Career Highlights: Throughout her career, Maura has anchored her research at esteemed institutions, notably the University of Padua and the University of Camerino. Her commitment to scientific advancement has positioned her as a key player in the intersection of inorganic chemistry and medicine, facilitating the development of targeted cancer treatments.
Collaborations: In her professional journey, Maura Pellei has collaborated with various esteemed colleagues, including Cristina Marzano and Marina Porchia. These partnerships underline the importance of teamwork in scientific research, which often leads to more innovative solutions and breakthroughs in complex medical challenges.
Conclusion: Maura Pellei's work exemplifies the vital role of inventors in the ongoing fight against cancer. Through her patent and collaboration with leading universities, she has laid the groundwork for potential advancements in cancer treatment. Her contributions continue to inspire future innovations in the search for effective therapies for solid tumors.